E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare overall survival between ZD1839 and docetaxel |
|
E.2.2 | Secondary objectives of the trial |
1. To compare TTP between ZD1839 and docetaxel 2. To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel 3. To compare the overall objective tumor response rate between ZD1839 and docetaxel 4. To compare patient-reported functionality (PRF) and QoL between ZD1839 and docetaxel 5. To compare safety and tolerability of ZD1839 and docetaxel |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Provision of written informed consent 2.Age 18 years or older 3.Histological or cytological confirmation of NSCLC (may be from initial diagnosis of NSCLC or subsequent biopsy). Note: sputum cytology alone is not acceptable. Cytological specimens obtained by brushing, washing or needle aspiration of a defined lesion are acceptable 4.Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy 5.One or two prior chemotherapy regimens, at least one of which must have been platinum-based. 6.Measurable (uni-dimensional) disease by RECIST criteria in a lesion not previously irradiated or non-measurable disease 7.WHO performance status (PS) 0-2 8.Absolute Neutrophil Count (ANC) greater than 1.5 x 10 to the power of 9/liter (L) and platelets greater than 100 x 10 to the power of 9/L 9.Adequate hepatic function, defined as BOTH a bilirubin less than or equal to upper limit of reference range (ULRR) AND an “Eligible” combination of transaminases (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) and alkaline phosphatase (ALP). 10.Recovery from all acute toxicities of prior therapies 11.Life expectancy of at least 8 weeks
|
|
E.4 | Principal exclusion criteria |
1.Prior ZD1839 therapy or prior therapy with an experimental agent whose primary mechanism of action is inhibition of EGFR or its associated tyrosine kinase 2.Prior docetaxel treatment for NSCLC 3.Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days 4.Less than 14 days since completion of prior radiotherapy or persistence of any radiotherapy related toxicity 5.Less than 21 days since prior chemotherapy, immunotherapy or biological systemic anticancer therapy 6.Any unresolved chronic toxicity from previous anticancer therapy that, in the opinion of the investigator, makes it inappropriate for the patient to be enrolled in the study 7.Known severe hypersensitivity to ZD1839 or any of the excipients of this product 8.Known hypersensitivity to docetaxel, polysorbate 80 or other drugs formulated with polysorbate 80, or any of the excipients of docetaxel 9.Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ 10.Unable to swallow tablets 11.Any evidence of clinically active ILD (patients with chronic, stable, radiographic changes who are asymptomatic or patients with uncomplicated progressive lymphangitic carcinomatosis need not be excluded) 12.As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic or renal disease) 13.Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study 14.Incomplete healing of the surgical incision from prior major surgery (small biopsy wounds will not prohibit the patient from study entry) 15.Signs of neurological symptoms consistent with new onset spinal cord compression 16.Patients with pre-existing peripheral neuropathy greater than or equal to grade 2 (NCI CTC criteria) 17.Pregnancy or breast feeding (women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control throughout the study to prevent pregnancy 18.Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates or St John’s Wort 19.Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of this study is to compare the overall survival between ZD1839 and docetaxel. The goal is to demonstrate non-inferior or superior survival for ZD1839 compared with docetaxel. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |